This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Injecting Drug Users in New York City, 1984 Through 1992

Don C. Des Jarlais, PhD; Samuel R. Friedman, PhD; Jo L. Sotheran, MA; John Wenston, MA; Michael Marmor, PhD; Stanley R. Yancovitz, MD; Blanche Frank, PhD; Sara Beatrice, PhD; Donna Mildvan, MD

JAMA. 1994;271(2):121-127.

Abstract
Objectives.
—To examine trends in acquired immunodeficiency syndrome (AIDS) risk behavior and human immunodeficiency virus (HIV) seroprevalence among injecting drug users (IDUs) in New York City from 1984 through 1992.

Design and Setting.
—Comparisons were made between two surveys of IDUs at the same hospital-based New York City drug abuse detoxification program: 141 IDUs in 1984 and 974 IDUs in 1990 through 1992. National Death Registry, New York City Health Department, and drug treatment program records were also used.

Participants.
—Persons attending detoxification program randomly selected for participation. Eligibility was based on injection within previous 2 months; 99% acceptance rates were obtained. Participants in the 1984 and 1990 through 1992 surveys were 66% and 79% men, 21% and 19% white, 33% and 34% African American, and 45% and 46% Latin American, respectively.

Interventions.
—Community-based AIDS prevention programs, including underground syringe exchanges.

Main Outcome Measures.
—Acquired immunodeficiency syndrome risk behaviors; HIV serostatus; CD4+ cell counts; death rates among 1984 subjects; and injection and intranasal routes of drug administration.

Results.
—The HIV seroprevalence remained stable at slightly more than 50%. Mean CD4⁺ cell counts declined from 0.716x10⁹/L (716/µL) to 0.575x10⁹/L (P<.009). Annual death rate among 1984 subjects was 3%, with a significantly higher rate among HIV-seropositive subjects (relative risk, 2.57; 95% exact binomial confidence interval, 1.12 to 6.61). Large-scale declines were observed in AIDS risk behaviors, eg, use of potentially contaminated syringes declined from 51% to 7% of injections (P<.001). Recent additional risk reduction was associated with use of the underground syringe exchanges. Intranasal heroin use was the primary route of drug administration for 46% of heroin admissions to New York City drug treatment programs.

Conclusions.
—The HIV seroprevalence has remained stable among this population of New York City IDUs for almost a decade. Continuation of current trends should lead to further reduction in HIV transmission, although reversal of the trend to intranasal use could lead to substantially increased transmission.

(JAMA. 1994;271:121-127)

Author Affiliations
From the Beth Israel Medical Center (Drs Des Jarlais, Yancovitz, and Mildvan), The Institute for AIDS Research, National Development and Research Institutes Inc (Dr Friedman, Ms Sotheran, and Mr Wenston), Department of Environmental Medicine, New York University (Dr Marmor), New York State Office of Alcoholism and Substance Abuse Services (Dr Frank), and New York City Department of Health (Dr Beatrice), New York, NY.

Footnotes
The views expressed herein do not necessarily reflect the positions of the granting agencies or of the institutions by which the authors are employed.

Reprint requests to Beth Israel Medical Center/ National Development and Research Institutes Inc, 11 Beach St, New York, NY 10013 (Dr Des Jarlais).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer et al.
Ann Fam Med 2007;5:146-150.
ABSTRACT | FULL TEXT  

HIV Incidence Among Injection Drug Users in New York City, 1990 to 2002: Use of Serologic Test Algorithm to Assess Expansion of HIV Prevention Services
Des Jarlais et al.
AJPH 2005;95:1439-1444.
ABSTRACT | FULL TEXT  

Optimal Investment in a Portfolio of HIV Prevention Programs
Zaric and Brandeau
Med Decis Making 2001;21:391-408.
ABSTRACT  

"War Stories": AIDS Prevention and the Street Narratives of Drug Users
Singer et al.
Qual Health Res 2001;11:589-611.
ABSTRACT  

Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions
van Ameijden and Coutinho
J. Epidemiol. Community Health 2001;55:356-363.
ABSTRACT | FULL TEXT  

Network-related Mechanisms May Help Explain Long-term HIV-1 Seroprevalence Levels That Remain High but Do Not Approach Population-Group Saturation
Friedman et al.
Am J Epidemiol 2000;152:913-922.
ABSTRACT | FULL TEXT  

An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users
Richter et al.
Med Decis Making 1999;19:167-179.
ABSTRACT  

The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study
Zaric et al.
SIMULATION 1998;71:262-275.
ABSTRACT  

New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes
Janssen et al.
JAMA 1998;280:42-48.
ABSTRACT | FULL TEXT  

AIDS in Women in the United States: Recent Trends
Wortley and Fleming
JAMA 1997;278:911-916.
ABSTRACT  

Prevention of HIV/AIDS and Other Blood-Borne Diseases Among Injection Drug Users: A National Survey on the Regulation of Syringes and Needles
Gostin et al.
JAMA 1997;277:53-62.
ABSTRACT  

AIDS Associated With Injecting-Drug Use-- United States, 1995
JAMA 1996;275:1628-1629.
 

Tuberculosis in New York City -- Turning the Tide
Frieden et al.
NEJM 1995;333:229-233.
ABSTRACT | FULL TEXT  

Temporal Trends of Incident Human Immunodeficiency Virus Infection in a Cohort of Injecting Drug Users in Baltimore, Md
Nelson et al.
Arch Intern Med 1995;155:1305-1311.
ABSTRACT  

Medical Care for Injection-Drug Users with Human Immunodeficiency Virus Infection
O'Connor et al.
NEJM 1994;331:450-459.
FULL TEXT  

Regulating Syringe Exchange Programs: A Cautionary Note
Jarlais et al.
JAMA 1994;272:431-432.
ABSTRACT  

Syringe and Needle Exchange to Prevent HIV Infection
Fernando
JAMA 1994;271:1825-1825.
ABSTRACT  

Addiction Medicine
Franklin
JAMA 1994;271:1650-1651.
ABSTRACT  

REDUCING HIV RISK IN DRUG INJECTORS: A PROGRESS REPORT
JWatch General 1994;1994:1-1.
FULL TEXT  

'Into Whatever Houses I Enter' HIV and Injecting Drug Use
Wartenberg
JAMA 1994;271:151-152.
ABSTRACT